SELLAS Life Sciences (SLS) Other Non-Current Liabilities (2011 - 2022)
SELLAS Life Sciences (SLS) posted quarterly Other Non-Current Liabilities of $170000.0 for Q3 2022, down 96.62% year-over-year from $5.0 million in Q3 2021, and down 6.08% quarter-over-quarter from $181000.0 in Q2 2022.
SELLAS Life Sciences (SLS) Other Non-Current Liabilities (2011 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other Non-Current Liabilities for 12 consecutive years, with $170000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Other Non-Current Liabilities fell 96.62% year-over-year to $170000.0; the TTM figure through Sep 2022 stood at $170000.0 (down 96.62% YoY), while the FY2021 annual figure was $296000.0, down 93.61% from the prior year.
- Other Non-Current Liabilities eased to $170000.0 in Q3 2022 per SLS's latest filing, from $181000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5.3 million in Q3 2018 and bottomed at $170000.0 in Q3 2022.
- Historically, Other Non-Current Liabilities has averaged $3.9 million across 5 years, with a median of $4.8 million in 2019.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities soared 320.29% — and 2022, when it plunged 96.62%.
- SELLAS Life Sciences' Other Non-Current Liabilities stood at $4.3 million in 2018, then advanced by 13.55% to $4.9 million in 2019, then fell by 5.68% to $4.6 million in 2020, then slumped by 93.61% to $296000.0 in 2021, then slumped by 42.57% to $170000.0 in 2022.
- Business Quant data shows SLS's Other Non-Current Liabilities at $170000.0 in Q3 2022, $181000.0 in Q2 2022, and $296000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 170,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Mar 31, 2022 | 296,000.00 |
| Dec 31, 2021 | 296,000.00 |
| Sep 30, 2021 | 5.04 Mn |
| Jun 30, 2021 | 4.90 Mn |
| Mar 31, 2021 | 4.76 Mn |
| Dec 31, 2020 | 4.63 Mn |
| Sep 30, 2020 | 5.18 Mn |
| Jun 30, 2020 | 5.19 Mn |
| Mar 31, 2020 | 5.05 Mn |
| Dec 31, 2019 | 4.91 Mn |
| Sep 30, 2019 | 4.84 Mn |
| Jun 30, 2019 | 4.81 Mn |
| Mar 31, 2019 | 4.71 Mn |
| Dec 31, 2018 | 4.33 Mn |
| Sep 30, 2018 | 5.32 Mn |
| Jun 30, 2018 | 5.16 Mn |
| Mar 31, 2018 | 4.71 Mn |
| Dec 31, 2017 | 1.29 Mn |